ForPatients
by Roche

Hemophilia A

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

Trial Status	Trial Runs In	Trial Identifier
Recruiting	6 Countries	NCT05987449 2023-503906-35-00 WP44714

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

WP44714 is a Phase I/II, open-label, non-randomized, global, multicenter trial consisting of two parts: * Part 1 is a multiple-ascending dose (MAD) study in adult and adolescent male participants with severe or moderate hemophilia A with or without factor VIII (FVIII) inhibitors. * Part 2 is a multiple-dose study in pediatric male participants with severe or moderate hemophilia A with or without FVIII inhibitors. The overall aim of the study is to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of NXT007.

Hoffmann-La Roche	Phase 1/Phase 2
Sponsor	Phase

NCT05987449 2023-503906-35-00 WP44714
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
Male	>=2 Years & <= 59 Years	No